NCT00175812View on ClinicalTrials.gov

Differentiation Induction in Acute Myelogenous Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

May 31, 2008

Study Completion Date

November 30, 2009

Conditions
Acute Myelogenous Leukemia
Interventions
DRUG

all-trans retinoic acid (ATRA)

All-trans retinoic acid 22.5 mg/square meter twice daily days 1-14

DRUG

Valproic acid

Valproic acid, highest dose without side effects from day 3 until progression

DRUG

Theophyllin

Theophyllin, targetted serum level 50-100 from day 3 until progression

Trial Locations (1)

N-5021

Haukeland University Hospital, University of Bergen, Bergen

All Listed Sponsors
lead

University of Bergen

OTHER

NCT00175812 - Differentiation Induction in Acute Myelogenous Leukemia | Biotech Hunter | Biotech Hunter